I agree that possibly only $10 immediately after a
Post# of 153902
(Total Views: 643)
Posted On: 01/03/2021 12:19:50 PM
Re: MD VIROLOGIST #70999
I agree that possibly only $10 immediately after approval. However, the rise in CYDY share price IMO, will be unique. Several factors have influenced an evolution in the effect that Breaking News has now, upon biotech share prices.
1) the disappointing efficacy of approved drugs, that were touted as game changers (remdesivir, plasma, Eli Lilly, Regeneron, steroids)
2) we've become immune to news about positive results
3) we/ve seen biotech stock price rise 60% in one day, based merely on the initiation of f Phase I study or a Phase II study
4) SRNE share price rose (not sure the %) I think 50% or more, based upon invitro testtube results their drug killing covid-19
5) MRNA and BNTX/PFE decline the day of and day after FDA approval
6) shorts and volatility, day traders and profit taking longs have made me weary of developing "ANY" expectations of probable share price movement following a Breaking News Press Release
So, due to the above and adding all the potential on-going forever catalysts, IMO, CYDY will remain very difficult to sell after share price goes up or down, and before or after any approval or other catalyst.
And, IMO, after approval for covid-19 s/c. share price may only go to 10. I think the big sp movement will come, as "results & recoveries & strong efficacy" is consistently displayed in the real world, not from trials. Thus, it will be more gradual than most of us anticipated, but may go to $30 by end of Feb, and then HIV and cancer will need to spark further upward movement. Just a bunch of common speculation from a layman. If Leronlimab persists as the only therapeutic with safe, strong efficacy, (or the main requested one) and it's effects are grand and broadcasted, sp will ????
I do pray leronlimab and vaccines and hopefully several other treatments will start saving lives asap and cause a downward turn in the curves of new cases and deaths.
1) the disappointing efficacy of approved drugs, that were touted as game changers (remdesivir, plasma, Eli Lilly, Regeneron, steroids)
2) we've become immune to news about positive results
3) we/ve seen biotech stock price rise 60% in one day, based merely on the initiation of f Phase I study or a Phase II study
4) SRNE share price rose (not sure the %) I think 50% or more, based upon invitro testtube results their drug killing covid-19
5) MRNA and BNTX/PFE decline the day of and day after FDA approval
6) shorts and volatility, day traders and profit taking longs have made me weary of developing "ANY" expectations of probable share price movement following a Breaking News Press Release
So, due to the above and adding all the potential on-going forever catalysts, IMO, CYDY will remain very difficult to sell after share price goes up or down, and before or after any approval or other catalyst.
And, IMO, after approval for covid-19 s/c. share price may only go to 10. I think the big sp movement will come, as "results & recoveries & strong efficacy" is consistently displayed in the real world, not from trials. Thus, it will be more gradual than most of us anticipated, but may go to $30 by end of Feb, and then HIV and cancer will need to spark further upward movement. Just a bunch of common speculation from a layman. If Leronlimab persists as the only therapeutic with safe, strong efficacy, (or the main requested one) and it's effects are grand and broadcasted, sp will ????
I do pray leronlimab and vaccines and hopefully several other treatments will start saving lives asap and cause a downward turn in the curves of new cases and deaths.
(5)
(0)